FDA Rejects Unicycive's Key Drug for Dialysis Patients, Major Setback for Biotech
UNCY sits 29% above its 52-week low of $3.71 on elevated volume (2.9× avg).
Summary
The US FDA has declined to approve Unicycive Therapeutics' drug for treating elevated phosphate levels in dialysis patients. This is a critical blow for the company, as this drug was a primary pipeline asset. The timeline shows Unicycive recently expanded its ATM offering to $150 million and filed a universal shelf registration, explicitly citing the need for liquidity ahead of this key FDA decision. The rejection severely impacts the company's future revenue potential and puts significant pressure on its financial runway.
At the time of this announcement, UNCY was trading at $4.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $205.6M. The 52-week trading range was $3.71 to $8.74. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Reuters.